Multisite Virtual Reality Intervention for Speech Anxiety

NCT06593847 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1542

Last updated 2025-12-18

No results posted yet for this study

Summary

Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.

Conditions

  • Public Speaking
  • Speech Anxiety

Interventions

BEHAVIORAL

Single-session VR exposure intervention

VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.

Sponsors & Collaborators

  • University of Texas at Austin

    collaborator OTHER
  • Curtin University

    collaborator OTHER
  • Erasmus University Rotterdam

    collaborator OTHER
  • National University of Singapore

    collaborator OTHER
  • Southern Illinois University

    collaborator OTHER
  • Tufts University

    collaborator OTHER
  • The University of New South Wales

    collaborator OTHER
  • University of Western Sydney

    collaborator OTHER
  • University of Arizona

    collaborator OTHER
  • The University of Hong Kong

    collaborator OTHER
  • Philipps Universität Marburg

    collaborator UNKNOWN
  • Albright College

    collaborator UNKNOWN
  • Utrecht University

    collaborator OTHER
  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Michael Otto, PhD · Boston University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2025-07-23
Completion
2025-07-23

Countries

  • United States
  • Australia
  • China
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06593847 on ClinicalTrials.gov